Serotonin 5-ht2 receptor interactions with dopamine function: Implications for therapeutics in cocaine use disorder

Pharmacological Reviews

Volumn 67, Issue 1, 2015, Pages 176-197

  Howell, Leonard L ^a   Cunningham, Kathryn A ^b  

^a EMORY UNIVERSITY   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; CENTRAL STIMULANT AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

ARTICLE; BEHAVIOR; BRAIN CORTEX; CELL FUNCTION; COCAINE DEPENDENCE; DOPAMINERGIC TRANSMISSION; DRUG DISCRIMINATION; DRUG SELF ADMINISTRATION; HUMAN; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NEUROSCIENCE; NEUROTRANSMISSION; NONHUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; ANIMAL; ANIMAL BEHAVIOR; BEHAVIOR, ADDICTIVE; BRAIN; COCAINE-RELATED DISORDERS; DISEASE MODEL; DRUG DESIGN; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PSYCHOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGENTS; SYNAPTIC TRANSMISSION;

EID: 84979860438     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/PR.114.009514     Document Type: Article

References (298)

1. Abbas A and Roth BL (2008) Arresting serotonin. Proc Natl Acad Sci USA 105: 831–832.
2. Abdallah L, Bonasera SJ, Hopf FW, O’Dell L, Giorgetti M, Jongsma M, Carra S, Pierucci M, Di Giovanni G, Esposito E, et al. (2009) Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function. J Neurosci 29:8156–8165.
3. Aghajanian GK and Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36:589–599.
4. Alex KD and Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296–320.
5. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, and Pehek EA (2005) Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 55:242–251.
6. Aloyo VJ, Berg KA, Spampinato U, Clarke WP, and Harvey JA (2009) Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors. Pharmacol Ther 121:160–173.
7. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. American Psychiatric Publishing, Arlington, VA.
8. Anastasio NC, Liu S, Maili L, Swinford SE, Lane SD, Fox RG, Hamon SC, Nielsen DA, Cunningham KA, and Moeller FG (2014a) Variation within the serotonin (5-HT) 5-HT₂C receptor system aligns with vulnerability to cocaine cue reactivity. Transl Psychiatr 4:e369.
9. Anastasio NC, Stoffel EC, Fox RG, Bubar MJ, Rice KC, Moeller FG, and Cunningham KA (2011) Serotonin (5-hydroxytryptamine) 5-HT(2A) receptor: association with inherent and cocaine-evoked behavioral disinhibition in rats. Behav Pharmacol 22: 248–261.
10. Anastasio NC, Stutz SJ, Fox RG, Sears RM, Emeson RB, DiLeone RJ, O’Neil RT, Fink LH, Li D, Green TA, et al. (2014b) Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. Neuropsychopharmacology 39:370–382.
11. Appel JB and Cunningham KA (1986) The use of drug discrimination procedures to characterize hallucinogenic drug actions. Psychopharmacol Bull 22:959–967.
12. Ator NA and Griffiths RR (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70(3, Suppl)S55–S72.
13. Auclair A, Blanc G, Glowinski J, and Tassin JP (2004) Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors. J Neurochem 91:318–326.
14. Auclair AL, Cathala A, Sarrazin F, Depoortère R, Piazza PV, Newman-Tancredi A, and Spampinato U (2010) The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem 114:1323–1332.
15. Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, and Nader MA (2008) Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology 33:219–225.
16. Bankson MG and Cunningham KA (2002) Pharmacological studies of the acute effects of (1)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26:40–52.
17. Barclay Z, Dickson L, Robertson DN, Johnson MS, Holland PJ, Rosie R, Sun L, Fleetwood-Walker S, Lutz EM, and Mitchell R (2011) 5-HT2A receptor signalling through phospholipase D1 associated with its C-terminal tail. Biochem J 436: 651–660.
18. Batki SL, Washburn AM, Delucchi K, and Jones RT (1996) A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 41:137–142.
19. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, and Rothman RB (2011) In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337:218–225.
20. Baumann MH and Rothman RB (1996) Chronic cocaine exposure potentiates prolactin and head shake responses to 5-HT2 receptor stimulation in rats. Neuropharmacology 35:295–301.
21. Baumann MH and Rothman RB (1998) Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol Psychiatry 44:578–591.
22. Béïque JC, Imad M, Mladenovic L, Gingrich JA, and Andrade R (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci USA 104:9870–9875.
23. Berg KA, Harvey JA, Spampinato U, and Clarke WP (2008) Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 172:287–305.
24. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, and Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology (Berl) 153:67–84.
25. Bevilacqua L, Doly S, Kaprio J, Yuan Q, Tikkanen R, Paunio T, Zhou Z, Wedenoja J, Maroteaux L, Diaz S, et al. (2010) A population-specific HTR2B stop codon pre-disposes to severe impulsivity. Nature 468:1061–1066.
26. Bevilacqua L and Goldman D (2013) Genetics of impulsive behaviour. Philos Trans R Soc Lond B Biol Sci 368:20120380.
27. Bjork JM, Moeller FG, Dougherty DM, Swann AC, Machado MA, and Hanis CL (2002) Serotonin 2a receptor T102C polymorphism and impaired impulse control. Am J Med Genet 114:336–339.
28. Blokland A, Sik A, and Lieben C (2005) Evaluation of DOI, 8-OH-DPAT, eticlopride and amphetamine on impulsive responding in a reaction time task in rats. Behav Pharmacol 16:93–100.
29. Bockaert J, Claeysen S, Bécamel C, Dumuis A, and Marin P (2006) Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res 326:553–572.
30. Booth RG, Fang L, Huang Y, Wilczynski A, and Sivendran S (2009) (1R, 3S)-(-)-trans PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. Eur J Pharmacol 615:1–9.
31. Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, and Artigas F (2005) The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95:1597–1607.
32. Bough KJ, Amur S, Lao G, Hemby SE, Tannu NS, Kampman KM, Schmitz JM, Martinez D, Merchant KM, Green C, et al. (2014) Biomarkers for the development of new medications for cocaine dependence. Neuropsychopharmacology 39:202–219.
33. Bowers BJ, Henry MB, Thielen RJ, and McBride WJ (2000) Serotonin 5-HT(2) receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J Neurochem 75:1625–1633.
34. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, et al. (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19:591–611.
35. Broderick PA, Olabisi OA, Rahni DN, and Zhou Y (2004) Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies. Prog Neuropsychopharmacol Biol Psychiatry 28:547–557.
36. Bromidge SM, Dabbs S, Davies DT, Davies S, Duckworth DM, Forbes IT, Gaster LM, Ham P, Jones GE, King FD, et al. (2000) Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem 43:1123–1134.
37. Bruce KR, Steiger H, Joober R, Ng Ying Kin NM, Israel M, and Young SN (2005) Association of the promoter polymorphism-1438G/A of the 5-HT2A receptor gene with behavioral impulsiveness and serotonin function in women with bulimia nervosa. Am J Med Genet B Neuropsychiatr Genet 137B:40–44.
38. Bubar MJ and Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971–1985.
39. Bubar MJ and Cunningham KA (2007) Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146:286–297.
40. Bubar MJ and Cunningham KA (2008) Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog Brain Res 172:319–346.
41. Bubar MJ, Stutz SJ, and Cunningham KA (2011) 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway. PLoS ONE 6: e20508.
42. Burbassi S and Cervo L (2008) Stimulation of serotonin2C receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats. Psychopharmacology (Berl) 196:15–27.
43. Burmeister JJ, Lungren EM, Kirschner KF, and Neisewander JL (2004) Differential roles of 5-HT receptor subtypes in cue and cocaine reinstatement of cocaine-seeking behavior in rats. Neuropsychopharmacology 29:660–668.
44. Burnet PW, Smith KA, Cowen PJ, Fairburn CG, and Harrison PJ (1999) Allelic variation of the 5-HT2C receptor (HTR2C) in bulimia nervosa and binge eating disorder. Psychiatr Genet 9:101–104.
45. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, and Perry KW (2002) Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160:353–361.
46. Callahan PM and Cunningham KA (1995) Modulation of the discriminative stimulus properties of cocaine by 5-HT1B and 5-HT2C receptors. J Pharmacol Exp Ther 274: 1414–1424.
47. Callahan PM and Cunningham KA (1997) Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists. Neuropharmacology 36:373–381.
48. Carpenter KM, Martinez D, Vadhan NP, Barnes-Holmes D, and Nunes EV (2012) Measures of attentional bias and relational responding are associated with behavioral treatment outcome for cocaine dependence. Am J Drug Alcohol Abuse 38: 146–154.
49. Carrasco GA and Battaglia G (2007) Withdrawal from a single exposure to cocaine increases 5-HT2A receptor and G protein function. Neuroreport 18:51–55.
50. Carrasco GA, Van de Kar LD, Sullivan NR, Landry M, Garcia F, Muma NA, and Battaglia G (2006) Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience 143:7–13.
51. Carrel D, Simon A, Emerit MB, Rivals I, Leterrier C, Biard M, Hamon M, Darmon M, and Lenkei Z (2011) Axonal targeting of the 5-HT1B serotonin receptor relies on structure-specific constitutive activation. Traffic 12:1501–1520.
52. Carter BL and Tiffany ST (1999) Cue-reactivity and the future of addiction research. Addiction 94:349–351.
53. Carter LP and Griffiths RR (2009) Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105 (Suppl 1):S14–S25.
54. Catterall WA and Mackie K (2005) Local anesthetics, in The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE eds) pp 369–388, McGraw-Hill, New York.
55. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, and O’Brien CP (1999) Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156: 11–18.
56. Ciraulo DA, Sarid-Segal O, Knapp CM, Ciraulo AM, LoCastro J, Bloch DA, Montgomery MA, Leiderman DB, and Elkashef A (2005) Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction 100 (Suppl 1):12–22.
57. Clark RN, Ashby CR Jr, Dewey SL, Ramachandran PV, and Strecker RE (1996) Effect of acute and chronic fluoxetine on extracellular dopamine levels in the caudate-putamen and nucleus accumbens of rat. Synapse 23:125–131.
58. Clemett DA, Punhani T, Duxon MS, Blackburn TP, and Fone KC (2000) Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 39:123–132.
59. Colpaert FC (1999) Drug discrimination in neurobiology. Pharmacol Biochem Behav 64:337–345.
60. Comer SD, Ashworth JB, Foltin RW, Johanson CE, Zacny JP, and Walsh SL (2008) The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96:1–15.
61. Cornea-Hébert V, Riad M, Wu C, Singh SK, and Descarries L (1999) Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409:187–209.
62. Cox SM, Benkelfat C, Dagher A, Delaney JS, Durand F, Kolivakis T, Casey KF, and Leyton M (2011) Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [¹¹C]raclopride study in humans. Br J Psychiatry 199:391–397.
63. Cox WM, Fadardi JS, and Pothos EM (2006) The addiction-stroop test: Theoretical considerations and procedural recommendations. Psychol Bull 132:443–476.
64. Cunningham BM (2010) Psychostimulants, in Encyclopedia of Psychopharmacology, Vol. 2 (Ip S ed) pp 1093–1100, Springer-Verlag, Berlin.
65. Cunningham K. A. and Anastasio N. C. (2014). Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 76: 460–478.
66. Cunningham KA, Anastasio NC, Fox RG, Stutz SJ, Bubar MJ, Swinford SE, Watson CS, Gilbertson SR, Rice KC, Rosenzweig-Lipson S, et al. (2013) Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction. ACS Chem Neurosci 4:110–121.
67. Cunningham KA and Callahan PM (1991) Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology (Berl) 104:177–180.
68. Cunningham KA, Fox RG, Anastasio NC, Bubar MJ, Stutz SJ, Moeller FG, Gilbertson SR, and Rosenzweig-Lipson S (2011) Selective serotonin 5-HT(2C) receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine-vs. sucrose-associated cues. Neuropharmacology 61:513–523.
69. Cunningham KA, Paris JM, and Goeders NE (1992) Chronic cocaine enhances serotonin autoregulation and serotonin uptake binding. Synapse 11:112–123.
70. Cussac D, Newman-Tancredi A, Quentric Y, Carpentier N, Poissonnet G, Parmentier JG, Goldstein S, and Millan MJ (2002) Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Arch Pharmacol 365:242–252.
71. Czoty PW, Ginsburg BC, and Howell LL (2002) Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300:831–837.
72. Dandy KL and Gatch MB (2009) The effects of chronic cocaine exposure on impulsivity in rats. Behav Pharmacol 20:400–405.
73. De Deurwaerdère P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235–3241.
74. De Deurwaerdère P and Spampinato U (1999) Role of serotonin(2A) and serotonin (2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J Neurochem 73: 1033–1042.
75. De La Garza R 2nd, Newton TF, and Kalechstein AD (2005) Risperidone diminishes cocaine-induced craving. Psychopharmacology (Berl) 178:347–350.
76. de Wit H (2009) Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 14:22–31.
77. Di Giovanni G, De Deurwaerdére P, Di Mascio M, Di Matteo V, Esposito E, and Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91:587–597.
78. Di Giovanni G, Di Matteo V, Di Mascio M, and Esposito E (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 35:53–61.
79. Di Mascio M, Di Giovanni G, Di Matteo V, Prisco S, and Esposito E (1998) Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 46:547–554.
80. Di Matteo V, Di Giovanni G, Di Mascio M, and Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195–1205.
81. Di Matteo V, Di Giovanni G, Pierucci M, and Esposito E (2008) Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 172:7–44.
82. Doherty MD and Pickel VM (2000) Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res 864: 176–185.
83. Dremencov E, El Mansari M, and Blier P (2009) Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci 34:223–229.
84. Ducci F and Goldman D (2012) The genetic basis of addictive disorders. Psychiatr Clin North Am 35:495–519.
85. Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, et al. (2005) WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J Pharmacol Exp Ther 313:862–869.
86. Eberle-Wang K, Mikeladze Z, Uryu K, and Chesselet MF (1997) Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384:233–247.
87. Egerton A, Ahmad R, Hirani E, and Grasby PM (2008) Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl) 200:487–496.
88. Evenden JL (1998) The pharmacology of impulsive behaviour in rats IV: the effects of selective serotonergic agents on a paced fixed consecutive number schedule. Psychopharmacology (Berl) 140:319–330 Berl.
89. Evenden JL and Ryan CN (1999) The pharmacology of impulsive behaviour in rats VI: the effects of ethanol and selective serotonergic drugs on response choice with varying delays of reinforcement. Psychopharmacology (Berl) 146:413–421 Berl.
90. EhrmanRN,RobbinsSJ,CornishJW,ChildressAR,andO’Brien CP (1996) Failure of ritanserin to block cocaine cue reactivity in humans. Drug Alcohol Depend 42:167–174.
91. Epstein DH, Preston KL, Stewart J, and Shaham Y (2006) Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 189:1–16.
92. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, and Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) 161:356–364.
93. Felder CC, Kanterman RY, Ma AL, and Axelrod J (1990) Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. Proc Natl Acad Sci USA 87:2187–2191.
94. Fentress HM, Grinde E, Mazurkiewicz JE, Backstrom JR, Herrick-Davis K, and Sanders-Bush E (2005) Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms. Pharmacogenomics J 5:244–254.
95. Field M and Cox WM (2008) Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend 97:1–20.
96. Filip M (2005) Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats. Pharmacol Rep 57:35–46.
97. Filip M, Bubar MJ, and Cunningham KA (2004) Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther 310: 1246–1254.
98. Filip M, Bubar MJ, and Cunningham KA (2006) Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats. Psychopharmacology (Berl) 183:482–489.
99. Filip M and Cunningham KA (2003) Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. J Pharmacol Exp Ther 306:734–743.
100. Filip M, Spampinato U, McCreary AC, and Przegalinski E (2012) Pharmacological and genetic interventions in serotonin (5-HT)(2C) receptors to alter drug abuse and dependence processes. Brain Res 1476:132–153.
101. Fleming JA, Byck R, and Barash PG (1990) Pharmacology and therapeutic applications of cocaine. Anesthesiology 73:518–531.
102. Fletcher PJ, Grottick AJ, and Higgins GA (2002) Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27:576–586.
103. Fletcher PJ, Rizos Z, Noble K, and Higgins GA (2011) Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade. Neuropharmacology 61:468–477.
104. Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, and Higgins GA (2008) The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology 33:1402–1412.
105. Fletcher PJ, Sinyard J, and Higgins GA (2006) The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology (Berl) 187:515–525.
106. Fletcher PJ, Tampakeras M, Sinyard J, and Higgins GA (2007) Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology (Berl) 195:223–234.
107. Foley KF (2005) Mechanism of action and therapeutic uses of psychostimulants. Clin Lab Sci 18:107–113.
108. Frankel PS and Cunningham KA (2004) m-Chlorophenylpiperazine (mCPP) modulates the discriminative stimulus effects of cocaine through actions at the 5-HT2C receptor. Behav Neurosci 118:157–162.
109. Frisch A, Michaelovsky E, Rockah R, Amir I, Hermesh H, Laor N, Fuchs C, Zohar J, Lerer B, Buniak SF, et al. (2000) Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. Eur Neuropsychopharmacol 10:205–209.
110. Fuchs RA, Tran-Nguyen LT, Specio SE, Groff RS, and Neisewander JL (1998) Predictive validity of the extinction/reinstatement model of drug craving. Psychopharmacology (Berl) 135:151–160.
111. Fuster JM (1997) The Prefrontal Cortex: Anatomy, Physiology, and Neuropsychology of the Frontal Lobe, 3rd edition. Lippincott-Raven, Philadelphia.
112. Gardner EL (2000) What we have learned about addiction from animal models of drug self-administration. Am J Addict 9:285–313.
113. Garoflos E, Stamatakis A, Mantelas A, Philippidis H, and Stylianopoulou F (2005) Cellular mechanisms underlying an effect of “early handling” on pCREB and BDNF in the neonatal rat hippocampus. Brain Res 1052:187–195.
114. Glennon RA and Young R (2011) Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies, John Wiley and Sons, Hoboken, NJ.
115. Glowa JR, Rice KC, Matecka D, and Rothman RB (1997) Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys. Neuroreport 8:1347–1351.
116. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, and Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36:205–221.
117. Gorelick DA (1998) The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 42:995–997.
118. Goudriaan AE, Veltman DJ, van den Brink W, Dom G, and Schmaal L (2013) Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: a randomized placebo-controlled cross-over study using pharmacological fMRI. Addict Behav 38:1509–1517.
119. Gould RW, Gage HD, Banks ML, Blaylock BL, Czoty PW, and Nader MA (2011) Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys. Neuropharmacology 61:245–251.
120. Grabowski J, Rhoades H, Elk R, Schmitz J, Davis C, Creson D, and Kirby K (1995) Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 15:163–174.
121. Grant S, London ED, Newlin DB, Villemagne VL, Liu X, Contoreggi C, Phillips RL, Kimes AS, and Margolin A (1996) Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci USA 93:12040–12045.
122. Grimm JW, Hope BT, Wise RA, and Shaham Y (2001) Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 412:141–142.
123. Grottick AJ, Fletcher PJ, and Higgins GA (2000) Studies to investigate the role of 5-HT(2C) receptors on cocaine-and food-maintained behavior. J Pharmacol Exp Ther 295:1183–1191.
124. Gu H, Salmeron BJ, Ross TJ, Geng X, Zhan W, Stein EA, and Yang Y (2010) Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity. Neuroimage 53:593–601.
125. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, and Schmauss C (2002) Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 34:349–356.
126. Hall H, Farde L, Halldin C, Lundkvist C, and Sedvall G (2000) Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse 38:421–431.
127. Halliday GM and Törk I (1989) Serotonin-like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum. Brain Res Bull 22:725–735.
128. Haney M and Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology (Berl) 199:403–419.
129. Hanlon CA, Beveridge TJ, and Porrino LJ (2013) Recovering from cocaine: insights from clinical and preclinical investigations. Neurosci Biobehav Rev 37 (9 Pt A):2037–2046.
130. Hanlon CA, Wesley MJ, Stapleton JR, Laurienti PJ, and Porrino LJ (2011) The association between frontal-striatal connectivity and sensorimotor control in cocaine users. Drug Alcohol Depend 115:240–243.
131. Hannon J and Hoyer D (2008) Molecular biology of 5-HT receptors. Behav Brain Res 195:198–213.
132. Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, et al. (2013) DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry 170:834–851.
133. Hayes DJ and Greenshaw AJ (2011) 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev 35:1419–1449.
134. Hebb MO and Robertson HA (2000) Identification of a subpopulation of substantia nigra pars compacta gamma-aminobutyric acid neurons that is regulated by basal ganglia activity. J Comp Neurol 416:30–44.
135. Hendershot CS, Witkiewitz K, George WH, and Marlatt GA (2011) Relapse prevention for addictive behaviors. Subst Abuse Treat Prev Policy 6:17.
136. Herin DV, Bubar MJ, Seitz PK, Thomas ML, Hillman GR, Tarasenko YI, Wu P, and Cunningham KA (2013) Elevated expression of serotonin 5-HT(2A) receptors in the rat ventral tegmental area enhances vulnerability to the behavioral effects of cocaine. Front Psychiatry 6: 2.
137. Herve D, Pickel VM, Joh TH, and Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435:71–83.
138. Holman BL, Carvalho PA, Mendelson J, Teoh SK, Nardin R, Hallgring E, Hebben N, and Johnson KA (1991) Brain perfusion is abnormal in cocaine-dependent polydrug users: a study using technetium-99m-HMPAO and ASPECT. JNuclMed32:1206–1210.
139. Holman BL, Mendelson J, Garada B, Teoh SK, Hallgring E, Johnson KA, and Mello NK (1993) Regional cerebral blood flow improves with treatment in chronic cocaine polydrug users. J Nucl Med 34:723–727.
140. Howell LL and Byrd LD (1995) Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J Pharmacol Exp Ther 275:1551–1559.
141. Howell LL and Negus SS (2014) Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol 69:129–176.
142. Huskinson SL, Naylor JE, Rowlett JK, and Freeman KB. (2014). Predicting abuse potential of stimulants and other dopaminergic drugs: Overview and recommendations. Neuropharmacology pii: S0028-3908(14)00094-X.
143. Ichikawa J and Meltzer HY (1995) Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 281:255–261.
144. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, and Innis RB (2000) Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry 157:1134–1140.
145. Jakab RL and Goldman-Rakic PS (1998) 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 95:735–740.
146. Jakab RL and Goldman-Rakic PS (2000) Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. JCompNeurol417:337–348.
147. Johanson CE and Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3–52.
148. Kalivas PW and McFarland K (2003) Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) 168:44–56.
149. Kalivas PW and Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162:1403–1413.
150. Kalivas PW and Volkow ND (2011) New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry 16:974–986.
151. Kandel ER (2005). Psychiatry, Psychoanalysis, and the New Biology of Mind, 1st ed, American Psychiatric Pub, Washington, DC.
152. Katritch V, Cherezov V, and Stevens RC (2012) Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 33:17–27.
153. Katritch V, Cherezov V, and Stevens RC (2013) Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:531–556.
154. Katsidoni V, Apazoglou K, and Panagis G (2011) Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine. Psychopharmacology (Berl) 213:337–354.
155. Katz JL and Higgins ST (2003) The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl) 168:21–30.
156. Kilts CD, Schweitzer JB, Quinn CK, Gross RE, Faber TL, Muhammad F, Ely TD, Hoffman JM, and Drexler KP (2001) Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry 58:334–341.
157. Kimmel HL, Manvich DF, Blough BE, Negus SS, and Howell LL (2009) Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol Biochem Behav 94:278–284.
158. Kirby LG, Zeeb FD, and Winstanley CA (2011) Contributions of serotonin in addiction vulnerability. Neuropharmacology 61:421–432.
159. Kittler K, Lau T, and Schloss P (2010) Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacol 629:63–67.
160. Kleven MS and Woolverton WL (1993) Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend 31:149–158.
161. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, and Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol 370:114–123.
162. Koob GF and Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238.
163. Kosofsky BE and Molliver ME (1987) The serotoninergic innervation of cerebral cortex: different classes of axon terminals arise from dorsal and median raphe nuclei. Synapse 1:153–168.
164. Koskinen T, Ruotsalainen S, and Sirviö J (2000) The 5-HT(2) receptor activation enhances impulsive responding without increasing motor activity in rats. Pharmacol Biochem Behav 66:729–738.
165. Kreiss DS and Lucki I (1995) Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274:866–876.
166. Kufahl PR, Li Z, Risinger RC, Rainey CJ, Wu G, Bloom AS, and Li SJ (2005) Neural responses to acute cocaine administration in the human brain detected by fMRI. Neuroimage 28:904–914.
167. Kuroki T, Meltzer HY, and Ichikawa J (2003) 5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 972: 216–221.
168. Kursar JD, Nelson DL, Wainscott DB, and Baez M (1994) Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol 46:227–234.
169. Labasque M, Reiter E, Becamel C, Bockaert J, and Marin P (2008) Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. Mol Biol Cell 19:4640–4650.
170. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, and Goldman D (1995) Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 27:274–279.
171. Leggio GM, Cathala A, Moison D, Cunningham KA, Piazza PV, and Spampinato U (2009a) Serotonin2C receptors in the medial prefrontal cortex facilitate cocaine-induced dopamine release in the rat nucleus accumbens. Neuropharmacology 56:507–513.
172. Leggio GM, Cathala A, Neny M, Rouge-Pont F, Drago F, Piazza PV, and Spampinato U (2009b) In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. J Neurochem 111:614–623.
173. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S, Del Favero J, Dikeos DG, Kaneva R, Lilli R, et al. (2001) Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 6:579–585.
174. LeSage MG, Stafford D, and Glowa JR (1999) Preclinical research on cocaine selfadministration: environmental determinants and their interaction with pharmacological treatment. Neurosci Biobehav Rev 23:717–741.
175. Levin JM, Holman BL, Mendelson JH, Teoh SK, Garada B, Johnson KA, and Springer S (1994) Gender differences in cerebral perfusion in cocaine abuse: technetium-99m-HMPAO SPECT study of drug-abusing women. J Nucl Med 35: 1902–1909.
176. Liégeois JF, Ichikawa J, and Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157–165.
177. Linley SB, Hoover WB, and Vertes RP (2013) Pattern of distribution of serotonergic fibers to the orbitomedial and insular cortex in the rat. J Chem Neuroanat 48-49: 29–45.
178. Liu S, Bubar MJ, Lanfranco MF, Hillman GR, and Cunningham KA (2007) Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction. Neuroscience 146: 1677–1688.
179. Loebl T, Angarita GA, Pachas GN, Huang KL, Lee SH, Nino J, Logvinenko T, Culhane MA, and Evins AE (2008) A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry 69: 480–486.
180. López-Giménez JF, Mengod G, Palacios JM, and Vilaró MT (1999) Human striosomes are enriched in 5-HT2A receptors: autoradiographical visualization with [3H]MDL100,907,[125I](+/-)DOI and [3H]ketanserin. Eur J Neurosci 11:3761–3765.
181. López-Giménez JF, Mengod G, Palacios JM, and Vilaró MT (2001a) Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 42:12–26.
182. López-Giménez JF, Vilaro MT, Palacios JM, and Mengod G (2001b) Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and in situ hybridization studies. J Comp Neurol 429(4):571-89.Lucki, I. (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44: 151–162.
183. Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44:151–162.
184. Ma N, Liu Y, Li N, Wang CX, Zhang H, Jiang XF, Xu HS, Fu XM, Hu X, and Zhang DR (2010) Addiction related alteration in resting-state brain connectivity. Neuroimage 49:738–744.
185. Maas LC, Lukas SE, Kaufman MJ, Weiss RD, Daniels SL, Rogers VW, Kukes TJ, and Renshaw PF (1998) Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. Am J Psychiatry 155:124–126.
186. Mamounas LA, Mullen CA, O’Hearn E, and Molliver ME (1991) Dual serotoninergic projections to forebrain in the rat: morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives. J Comp Neurol 314:558–586.
187. Manvich DF, Kimmel HL, Cooper DA, and Howell LL (2012b) The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys. JPharmacolExpTher342:761–769.
188. Manvich DF, Kimmel HL, and Howell LL (2012a) Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 341:424–434.
189. Marek GJ, Martin-Ruiz R, Abo A, and Artigas F (2005) The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 30:2205–2215.
190. Marhe R, van de Wetering BJ, and Franken IH (2013) Error-related brain activity predicts cocaine use after treatment at 3-month follow-up. Biol Psychiatry 73:782–788.
191. Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, et al. (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther 320:486–496.
192. Martin-Fardon R and Weiss F (2013) Modeling relapse in animals. Curr Top Behav Neurosci 13:403–432.
193. Mash DC, Staley JK, Izenwasser S, Basile M, and Ruttenber AJ (2000) Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat 20:271–280.
194. McCann AJ and Vocci FJ(2008). Drug discovery and development for reward disorders: views from government, in Reward Deficit Disorders, 3rded.,vol. 3, pp. 23–40, Academic Press, Burlington, VT.
195. McGrew L, Chang MS, and Sanders-Bush E (2002) Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits. Mol Pharmacol 62:1339–1343.
196. McGrew L, Price RD, Hackler E, Chang MS, and Sanders-Bush E (2004) RNA editing of the human serotonin 5-HT2C receptor disrupts transactivation of the small G-protein RhoA. Mol Pharmacol 65:252–256.
197. McMahon LR and Cunningham KA (2001) Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther 297:357–363.
198. McMahon LR, Filip M, and Cunningham KA (2001) Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Neurosci 21:7781–7787.
199. Mello NK and Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14:375–424.
200. Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA, Stohler CS, Goldman D, and Zubieta JK (2012) Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans. J Neurosci 32:9344–9350.
201. Millan MJ, Marin P, Bockaert J, and Mannoury la Cour C (2008) Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 29:454–464.
202. Miner LA, Backstrom JR, Sanders-Bush E, and Sesack SR (2003) Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 116:107–117.
203. Mitchell JB, Rowe W, Boksa P, and Meaney MJ (1990) Serotonin regulates type II corticosteroid receptor binding in hippocampal cell cultures. J Neurosci 10:1745–1752.
204. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, and Swann AC (2001a) Psychiatric aspects of impulsivity. Am J Psychiatry 158:1783–1793.
205. Moeller FG, Dougherty DM, Barratt ES, Schmitz JM, Swann AC, and Grabowski J (2001b) The impact of impulsivity on cocaine use and retention in treatment. J Subst Abuse Treat 21:193–198.
206. Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lai LY, Swann AC, and Grabowski J (2007) Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 33: 367–378.
207. Moeller FG, Steinberg JL, Lane SD, Kjome KL, Ma L, Ferre S, Schmitz JM, Green CE, Bandak SI, Renshaw PF, et al. (2012) Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects. Front Psychiatry 3:44.
208. Moya PR, Berg KA, Gutiérrez-Hernandez MA, Sáez-Briones P, Reyes-Parada M, Cassels BK, and Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 321:1054–1061.
209. Murnane KS, Andersen ML, Rice KC, and Howell LL (2013a) Selective serotonin 2A receptor antagonism attenuates the effects of amphetamine on arousal and dopamine overflow in non-human primates. J Sleep Res 22:581–588.
210. Murnane KS, Winschel J, Schmidt KT, Stewart LM, Rose SJ, Cheng K, Rice KC, and Howell LL (2013b) Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates. J Neurosci 33:13367–13374.
211. Navailles S and De Deurwaerdère P (2011) Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl) 213:213–242.
212. Navailles S, De Deurwaerdère P, Porras G, and Spampinato U (2004) In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. Neuropsychopharmacology 29:319–326.
213. Navailles S, De Deurwaerdère P, and Spampinato U (2006) Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Biol Psychiatry 59:568–575.
214. Navailles S, Moison D, Cunningham KA, and Spampinato U (2008) Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology 33:237–246.
215. Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, and Day M (2008) The 5-HT (2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behav Brain Res 188:412–415.
216. Negus SS, Mello NK, Blough BE, Baumann MH, and Rothman RB (2007) Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate “agonist” medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320:627–636.
217. Neisewander JL and Acosta JI (2007). Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats. Behav Pharmacol 18:791–800.
218. Newton TF, Ling W, Kalechstein AD, Uslaner J, and Tervo K (2001) Risperidone pretreatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 102:227–233.
219. Nic Dhonnchadha BA, Fox RG, Stutz SJ, Rice KC, and Cunningham KA (2009) Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. Behav Neurosci 123: 382–396.
220. Nocjar C, Roth BL, and Pehek EA (2002) Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group. Neuroscience 111: 163–176.
221. Nomura M, Kusumi I, Kaneko M, Masui T, Daiguji M, Ueno T, Koyama T, and Nomura Y (2006) Involvement of a polymorphism in the 5-HT2A receptor gene in impulsive behavior. Psychopharmacology (Berl) 187:30–35.
222. O’Brien CP (2006) Drug addiction and drug abuse, in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th ed. (Brunton L, Lazo J, and Parker K eds) pp 607–628, McGraw-Hill, New York.
223. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, and Goldman D (2004) Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 9:55–64.
224. Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, et al. (2012) Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction 107:131–141.
225. Overton DA (1987) Applications and limitations of the drug discrimination method for the study of drug abuse, in Methods of Assessing the Reinforcing Properties of Abused Drugs (Bozarth MJ, ed, ed) pp 291–340, Springer Verlag, New York.
226. Panlilio LV and Goldberg SR (2007) Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction 102:1863–1870.
227. Parent A, Descarries L, and Beaudet A (1981) Organization of ascending serotonin systems in the adult rat brain. A radioautographic study after intraventricular administration of [3H]5-hydroxytryptamine. Neuroscience 6:115–138.
228. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, and Nardi I (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92:601–611.
229. Pehek EA, McFarlane HG, Maguschak K, Price B, and Pluto CP (2001) M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex. Brain Res 888:51–59.
230. Pehek EA, Nocjar C, Roth BL, Byrd TA, and Mabrouk OS (2006) Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress-and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31: 265–277.
231. Pennanen L, van der Hart M, Yu L, and Tecott LH (2013) Impact of serotonin (5-HT)2C receptors on executive control processes. Neuropsychopharmacology 38:957–967.
232. Pentkowski NS, Duke FD, Weber SM, Pockros LA, Teer AP, Hamilton EC, Thiel KJ, and Neisewander JL (2010) Stimulation of medial prefrontal cortex serotonin 2C (5-HT(2C)) receptors attenuates cocaine-seeking behavior. Neuropsychopharmacology 35:2037–2048.
233. Perry KW and Fuller RW (1992) Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 50:1683–1690.
234. Pessia M, Jiang ZG, North RA, and Johnson SW (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654:324–330.
235. Pierce RC, O’Brien CP, Kenny PJ, and Vanderschuren LJ (2012) Rational development of addiction pharmacotherapies: successes, failures, and prospects. Cold Spring Harb Perspect Med 2:a012880.
236. Pittenger C and Kandel E (1998) A genetic switch for long-term memory. C R Acad Sci III 321:91–96.
237. Pockros LA, Pentkowski NS, Swinford SE, and Neisewander JL (2011) Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates reinstatement of cue-elicited cocaine-seeking behavior in rats. Psychopharmacology (Berl) 213:307–320.
238. Pompeiano M, Palacios JM, and Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163–178.
239. Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdère P, Caccia S, Esposito E, and Spampinato U (2002) 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26:311–324.
240. Porter RH, Benwell KR, Lamb H, Malcolm CS, Allen NH, Revell DF, Adams DR, and Sheardown MJ (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br J Pharmacol 128:13–20.
241. Qu Y, Aluisio L, Lord B, Boggs J, Hoey K, Mazur C, and Lovenberg T (2009) Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. Pharmacol Biochem Behav 92:469–473.
242. Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, MacGregor RR, Shiue CY, Atkins H, Anand A, et al. (1985) Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab 5:179–192.
243. Ritz MC, Lamb RJ, Goldberg SR, and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223.
244. Robertson DN, Johnson MS, Moggach LO, Holland PJ, Lutz EM, and Mitchell R (2003) Selective interaction of ARF1 with the carboxy-terminal tail domain of the 5-HT2A receptor. Mol Pharmacol 64:1239–1250.
245. Rocha BA, Goulding EH, O’Dell LE, Mead AN, Coufal NG, Parsons LH, and Tecott LH (2002) Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. J Neurosci 22:10039–10045.
246. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA, Lu Y, Mansbach RS, Mather RJ, Rovetti CC, et al. (2007) Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985–994.
247. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836–2841.
248. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, and Baumann MH (2005). Development of a rationally designed, low abuse potential, biogenic amine. J Pharmacol Exp Ther 313:1361–1369.
249. Ruedi-Bettschen D, Rowlett JK, Spealman RD, and Platt DM (2010) Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms. Psychopharmacology (Berl) 210:169–177.
250. Santana N, Bortolozzi A, Serrats J, Mengod G, and Artigas F (2004) Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14:1100–1109.
251. Sawyer EK, Mun J, Nye JA, Kimmel HL, Voll RJ, Stehouwer JS, Rice KC, Goodman MM, and Howell LL (2012) Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use. Neuropsychopharmacology 37:1816–1824.
252. Schama KF, Howell LL, and Byrd LD (1997). Serotonergic modulation of the discriminative-stimulus effects of cocaine in squirrel monkeys. Psychopharmacology (Berl) 132:27–34.
253. Schenk S (2000) Effects of the serotonin 5-HT(2) antagonist, ritanserin, and the serotonin 5-HT(1A) antagonist, WAY 100635, on cocaine-seeking in rats. Pharmacol Biochem Behav 67:363–369.
254. Schmid CL and Bohn LM (2010) Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 30:13513–13524.
255. Schmid CL, Raehal KM, and Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079–1084.
256. Schmitz JM, Mooney ME, Green CE, Lane SD, Steinberg JL, Swann AC, and Moeller FG (2009) Baseline neurocognitive profiles differentiate abstainers and non-abstainers in a cocaine clinical trial. J Addict Dis 28:250–257.
257. Schuster CR and Johanson CE (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol Ser 4:161–175.
258. Serretti A, Lilli R, Lorenzi C, Lattuada E, and Smeraldi E (2000) Serotonin-2C and serotonin-1A receptor genes are not associated with psychotic symptomatology of mood disorders. Am J Med Genet 96:161–166.
259. Setlow B, Mendez IA, Mitchell MR, and Simon NW (2009) Effects of chronic administration of drugs of abuse on impulsive choice (delay discounting) in animal models. Behav Pharmacol 20:380–389.
260. Shaham Y, Shalev U, Lu L, De Wit H, and Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168:3–20.
261. Shashack MJ, Cunningham KA, Seitz PK, McGinnis A, Smith T, Watson CS, and Gilbertson SR (2011) Synthesis and evaluation of dimeric derivatives of 5-HT (2A) receptor (5-HT(2A)R) antagonist M-100907. ACS Chem Neurosci 2:640–644.
262. Simpson DD, Joe GW, and Broome KM (2002) A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 59:538–544.
263. Simpson DD, Joe GW, Fletcher BW, Hubbard RL, and Anglin MD (1999) A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 56: 507–514.
264. Skolnick P and Volkow ND (2012) Addiction therapeutics: obstacles and opportunities. Biol Psychiatry 72:890–891.
265. Smythe JW, Rowe WB, and Meaney MJ (1994) Neonatal handling alters serotonin (5-HT) turnover and 5-HT2 receptor binding in selected brain regions: relationship to the handling effect on glucocorticoid receptor expression. Brain Res Dev Brain Res 80:183–189.
266. Spealman RD (1993) Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology (Berl) 112:93–99.
267. Stoltenberg SF, Christ CC, and Highland KB (2012) Serotonin system gene polymorphisms are associated with impulsivity in a context dependent manner. Prog Neuropsychopharmacol Biol Psychiatry 39:182–191.
268. Strickland TL, Mena I, Villanueva-Meyer J, Miller BL, Cummings J, Mehringer CM, Satz P, and Myers H (1993) Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J Neuropsychiatry Clin Neurosci 5:419–427.
269. Sutherland MT, McHugh MJ, Pariyadath V, and Stein EA (2012) Resting state functional connectivity in addiction: Lessons learned and a road ahead. Neuroimage 62:2281–2295.
270. Teuns GB, Geys HM, Geuens SM, Stinissen P, and Meert TF (2014). Abuse liability assessment in preclinical drug development: Predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models. J Pharmacol Toxicol Methods pii: S1056-8719(14)00026-4.
271. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, et al. (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325:577–587.
272. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, et al. (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methyl-propyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 317:910–918.
273. Varnäs K, Halldin C, and Hall H (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum Brain Mapp 22:246–260.
274. Vázquez-Borsetti P, Celada P, Cortés R, and Artigas F (2011) Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei. Int J Neuropsychopharmacol 14:289–302.
275. Vázquez-Borsetti P, Cortés R, and Artigas F (2009) Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex 19:1678–1686.
276. Vertes LS (2008) Efferent and Afferent Connections of the Dorsal and Median Raphe Nuclei in the Rat, Birkhauser Verlag, Switzerland
277. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, Franceschi D, Gatley J, Hitzemann R, et al. (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158:2015–2021.
278. Volkow ND, Fowler JS, Wolf AP, Hitzemann R, Dewey S, Bendriem B, Alpert R, and Hoff A (1991) Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 148:621–626.
279. Volkow ND, Mullani N, Gould KL, Adler S, and Krajewski K (1988) Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry 152:641–648.
280. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, and Pappas N (1999) Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 156:19–26.
281. Walsh SL, Preston KL, Sullivan JT, Fromme R, and Bigelow GE (1994) Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14:396–407.
282. Walstab J, Steinhagen F, Brüss M, Göthert M, and Bönisch H (2011) Differences between human wild-type and C23S variant 5-HT2C receptors in inverse agonist-induced resensitization. Pharmacol Rep 63:45–53.
283. Walther DJ and Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66:1673–1680.
284. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, and Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848–854.
285. Weiss F. (2010). Advances in Animal Models of Relapse for Addiction Research.CRC Press, Florida.
286. Weiss F and Koob GF (2001) Drug addiction: functional neurotoxicity of the brain reward systems. Neurotox Res 3:145–156.
287. Werry TD, Christopoulos A, and Sexton PM (2006) Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 12:1683–1702.
288. Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, and Gore JC (2001) Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry 158:86–95.
289. Wilcox CE, Teshiba TM, Merideth F, Ling J, and Mayer AR (2011) Enhanced cue reactivity and fronto-striatal functional connectivity in cocaine use disorders. Drug Alcohol Depend 115:137–144.
290. Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Montgomery MA, Goldsmith RJ, Coleman FS, Bloch DA, Leiderman DB, Singal BM, et al. (2005) A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 100 (Suppl 1):68–77.
291. Winstanley CA, Bachtell RK, Theobald DE, Laali S, Green TA, Kumar A, Chakravarty S, Self DW, and Nestler EJ (2009) Increased impulsivity during withdrawal from cocaine self-administration: role for DeltaFosB in the orbitofrontal cortex. Cereb Cortex 19:435–444.
292. Winstanley CA, Chudasama Y, Dalley JW, Theobald DE, Glennon JC, and Robbins TW (2003) Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) 167:304–314.
293. Winstanley CA, Olausson P, Taylor JR, and Jentsch JD (2010) Insight into the relationship between impulsivity and substance abuse from studies using animal models. Alcohol Clin Exp Res 34:1306–1318.
294. Winstanley CA, Theobald DE, Dalley JW, Glennon JC, and Robbins TW (2004) 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl) 176:376–385.
295. Wong DT, Bymaster FP, and Engleman EA (1995) Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411–441.
296. Woolverton WL and Kleven MS (1988) Multiple dopamine receptors and the behavioral effects of cocaine. NIDA Res Monogr 88:160–184.
297. Yan QS (2000) Activation of 5-HT2A/2C receptors within the nucleus accumbens increases local dopaminergic transmission. Brain Res Bull 51:75–81.
298. Zayara AE, McIver G, Valdivia PN, Lominac KD, McCreary AC, and Szumlinski KK (2011) Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology (Berl) 213:321–335.